Key Takeaways
- Delayed but derisked: Phase 1 commercialization slipped from October 2025 to end-June 2026, but the CTO license is expected by June 25th and the team is already in place, so the remaining risk is compressed into a single regulatory clearance.
- Premium mix shift drove H2: SMCC and Spheres exports ramped in H2, lifting the export share to ~63% and setting a higher-margin baseline that management expects to sustain into FY27.
- Trading inflated the topline, not the bottom: Trading volumes filled the gap while own capacity was capped at 10,000 MT, but at 2–5% margins they diluted blended profitability; a material unwind waits on Phase 2 commercialization.
- CCS is the eight-year bet: The company will be India's first to make CMC from wood pulp and process it into CCS, with 40–50 successful trial samples already produced; Phase 1's 2,400 MT is fungible across CCS, SSG and CMC.
- What to watch next quarter: Whether the CTO license clears by June 25th and commercial production begins, the pace of premium product share expansion toward 16–17%, and any working capital normalization after the year-end receivables buildup.
Phase 1 Commercialization: The Critical Path
- Delay drivers: Two consecutive abnormal monsoons and licensing work for what regulators treat as a greenfield project pushed the timeline from October 2025 to April 2026, and now to end-June 2026.
- What is already done: Technology transfer from the head plant to Navagam is complete, all documentation is in place, and QC, QA and GM operations manpower have nearly all joined.
- The final gate: Consent to Establish was already secured; the file for Consent to Operate and the pollution control license has been resubmitted after a 15-day election-related pause and is expected to clear by June 25th.
- Ramp-up assumption: Once approvals come, the company does not foresee challenges starting production; 50 kg of sample was already produced at Dahej and sold at premium margin, so the process is proven.
- First-year utilization: Management expects 50–60% utilization on a per-day basis over roughly 9 months of production in FY27, not peak capacity.
Mr. Nitin: "due to election the officials were inactive from last 15 days that caused the delay but we submit the file again till June 25th file it will be clear."
Product Mix & Margin Trajectory
- The H2 premium shift: SMCC and MCC Spheres, both high-value products, were exported more heavily in H2; MCC was diverted to captive consumption as raw material for these downstream products rather than sold directly.
- Export mix moved with it: Export revenue rose from 53% to ~63% of sales, driven by Spheres being almost 90% exported; management expects this ratio to increase further as Phase 1 adds only premium export-oriented capacity.
- Realization math: The weighted average realization of ₹250–260 per kg reflects a 40% domestic share where realizations are ₹170–190 per kg; the export premium is substantial.
- Margin ambition: Management expects blended profit margins to increase by at least 2–3 percentage points as the premium product share rises, with an ultimate aim to move from ~16% to 18–20%.
- Phase 1 and 2 margin hierarchy: It is prudent to assume Phase 1 EBITDA margins will be higher than the company average, and Phase 2 even higher, as fixed costs get spread across a larger base.
- Trading dilution: Trading carries 2–5% margins versus blended company margins; this drag persists until Phase 2 commercialization, not Phase 1, because Phase 1 capacity is targeted at CCS and premium products, not at replacing traded MCC volumes.
Accent Microcell Ltd.: "It will be prudent enough to assume going ahead, as we are going ahead with more premium range of products, so it is prudent enough to assume that the blended profit margins are going to increase by, say, at least 2-3 percentage."
CCS: The Differentiated Technology Bet
- Eight-year R&D payoff: The company spent 8 years developing the technology to make CMC from wood pulp and process it forward into CCS; 40–50 trial samples were prepared at the Dahej plant and were successful.
- India-first claim: Management states the company will be India's first plant with this integrated wood-pulp-to-CCS capability, a claim it distinguishes from the MCC Spheres technology where it acknowledges other players exist.
- Phase 1 fungibility: The 2,400 MT capacity can produce CCS, SSG or CMC; current targeting favors CCS based on identified customer demand.
- Customer readiness: A mixture of existing and new customers has already been identified; the existing base is expected to buy CCS output. New customer additions for the CCS product line are an ongoing process.
- Trial-to-commercial gap: Post receipt of required approvals, at least 20–25 days of trial run activities are needed because the process is ethanol-based, after which commercial production and dispatch can begin.
- Competitive reality: Management acknowledges most global MCC players are already in CCS, so competition exists, but argues its identified customer set insulates the initial ramp.
Accent Microcell Ltd.: "This technology took us almost 8 years of R&D to develop. After 8 years of R&D we are successfully bringing this product to the market."
Trading Volumes: Strategic Bridge or Margin Anchor
- Why trading grew: The customer onboarding and stability approval process is long; trading semi-processed MCC (where the company performs finishing steps like sifting, drying and accuracy checks) kept customers engaged while own capacity was fully utilized.
- Scale of the gap: Sales volumes of 15,000 MT exceeded own production capacity of 10,000 MT, with the difference made up by traded volumes.
- Margin impact: Trading margins range from 2–3% for some customers to ~5% on the higher side, well below blended company margins; this weighed on consolidated profitability in FY26.
- Unwind timing: A substantial decrease in trading volumes is expected only once Phase 2 goes live, because Phase 1 is dedicated to premium products (CCS, SSG, CMC) rather than MCC. Until Phase 2 commercialization, a certain portion of trading will continue.
- Strategic rationale: Management frames trading as a prudent business decision to encase opportunity and retain customers through a multi-year qualification cycle, not as a permanent feature of the model.
Accent Microcell Ltd.: "it was mere to encase the business opportunity that any businessman... it is very prudent for a businessman to ensure that the existing customer base remains with the, say, the... say, it is a long process, stability approval and all those stuffs, and to get the customer on board."
Unit Economics & Cost Structure
- Raw material sourcing: Wood pulp is imported from the USA, Sweden, Canada and Indonesia; the company does not import from China.
- Cost pass-through and natural hedge: Any nominal increase in wood pulp import costs has been completely passed on to customers; exports run roughly 3x imports, so currency depreciation provides a net positive benefit.
- Geopolitical impact limited: No price fluctuation from geopolitical tensions has materialized, only transit time delays; adequate raw material hedges are in place.
- Pirana vs Dahej economics: Pirana uses non-spray dryer technology and serves the domestic market at lower realizations; Dahej (SEZ) uses spray dryer technology for exports at higher realizations. Pirana is profitable but at lower margins (₹8.5 cr on ₹150 cr revenue), partly due to an exceptional item from new labor laws.
- Working capital normalization: Receivables that built up at FY26 year-end have already normalized to a certain extent; management expects the working capital position to be addressed if not by H1 FY27, then surely by FY27 end.
Phase 2 & Beyond: The Capacity Roadmap
- Phase 2 timeline: Previously expected in H2 FY27, now delayed to H1 FY28; management calls even the March 2027 target premature to commit to firmly, citing regulatory requirements, stability approvals and database work as variables beyond its control.
- Phase 2 scope: Will produce MCC using both spray and non-spray technology, targeting global markets and Indian MNCs; the initial phase may also address domestic demand.
- Phase 2 funding: To be funded from the rights issue proceeds and, to a certain extent, internal accruals; no debt is planned.
- Phase 3 and beyond: Land has been purchased for up to Phase 6; Phase 3 is tentatively eyed for 2028 but management will only declare plans after Phase 2 succeeds. Internal accruals are expected to suffice for future phases, with no debt requirements foreseen.
- Rights issue rationale: Management chose equity over debt to gain competitive advantage at an early stage, acknowledging it understands the benefit of leverage but prioritized speed and flexibility.
Accent Microcell Ltd.: "Sir, it was an... it was a kind of an, management, discretion, and we completely understand about the benefit of the leverage as well, but in order to gain competitive advantage, or at an early stage, we opted to go for right issue instead of debt."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CTO license clearance | File submitted; clearance expected by June 25th | June 2026 |
| Phase 1 commercial production | Start production once CTO received; 20–25 days of trial runs needed for CCS | Q2 FY27 (post-approvals) |
| Phase 1 first-year utilization | 50–60% of peak capacity on a per-day basis, over 9 months of production | FY27 |
| Phase 1 peak revenue | Approximately ₹150 cr at full capacity, plus/minus 5–10% | At peak utilization (undated) |
| Phase 2 commercialization | Delayed from H2 FY27 to H1 FY28; conservative timeline shared | H1 FY28 |
| Trading volume reduction | Substantial decrease expected once Phase 2 goes live | H1 FY28 (conditional on Phase 2) |
| Premium product share | Gradually increasing from 13% to 16–17% | FY27 |
| Blended margin improvement | At least 2–3 percentage point increase as premium mix rises | Undated (trend-based) |
| Working capital normalization | If not by H1 FY27, surely by FY27 end | FY27 |
| Distributor vs direct sales mix | Remain around 85–15% | Ongoing |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue from operations | Figures uploaded with NSE portal, YoY increase in revenue, EBITDA, PAT margins, and PAT |
| Export share of revenue | 63%, up from 53% last year |
| Total sales volume | 15,000 metric tons in FY26 |
| Installed capacity (both plants) | 10,000 metric tons (9,200 for MCC only; converting to MCC spheres increases volume) |
| Manufacturing vs traded volume split | 70% manufacturing, 25-30% traded |
| Gross profit percentage | 38% |
| Trading margin | 4-5% |
| Order book | 4,000 metric tons on hand |
| Premium products share of revenue | 13% in FY26 |
| MCC Spheres capacity | 100 metric tons per month |
| Trade receivables | ₹90 crores |
| Purchase of stock in trade | ₹95 crores in FY26 P&L |
| Trading product split | 90% MCC, rest MS and cellulose powder |
| Trading geographic split | 70% domestic, 30% export |
| Pirana unit revenue | ₹153 crores in FY26 |
| Pirana unit profit | ₹8.5 crores |
| Cash on balance sheet | ₹20 crores |
| Distributor vs direct sales split | 85% distributor, 15% direct |
| Domestic realization | ₹170 to ₹190 per kg |
| Weighted average realization | ₹250 to ₹260 per kg |
| Phase 1 peak revenue potential | ₹150 crores |
| Phase 2 peak revenue potential | ₹200 crores |
| Phase 1 expected utilization in FY27 | 50-60%, over 9 months of production |
| Phase 2 expected utilization from first year | 75-80% |
| Phase 1 product realization | ₹600 per kg |
| Phase 2 product realization | ₹180 to ₹200 per kg |
| Unit 3 Phase 1 average realization | ₹650 to ₹700 per unit |
| CMC domestic selling price | ₹400 per kg |
| CMC export selling price | ₹800 to ₹900 per kg |
| CCS customer split | 80-90% export, remaining domestic |
| Expected premium product share in FY27 | 16-17% |
| Phase 1 revenue as share of existing Unit 1 and 2 revenue | 40% at peak capacity |
| Industry growth: pharma and nutra | 6.9% |
| Industry growth: food and beverages | 5.1% |
| Industry growth: cosmetics | 5.6% |
| Industry growth: pet industry | 4.6% |
| Industry growth: industrial segment | 5.1% |